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Implantable cardioverter defibrillators (ICDs) are used to treat life-threatening cardiac
arrhythmias and prevent sudden cardiac arrest. As recipients age they may develop a greater
risk of dying as a result of progressive multimorbidity rather than sudden cardiac death.
Defibrillation shocks may prolong an uncomfortable dying process. Deactivation of the
defibrillator would prevent this, yet is not always discussed and planned.
Aim:
To systematically review published evidence on ICD deactivation discussions, and make
recommendations on when, how and who should facilitate effective and patient-centred
deactivation discussions.
Method:
Using standard systematic review methods, MEDLINE, EMBASE, CINAHL and PsycInfo were
searched for studies published in the English language between 2010 and March 2021.
Inclusion criteria: studies of adults (≥18 years) and including discussions on ICD deactivation
and/or related communication. Included studies were independently reviewed, data
extracted, quality assessed, and data were synthesised using a deductive approach.
Results:
Of the 8893 articles identified, 22 papers met inclusion criteria. Deductive approach led to
the identification of five main themes: (1) timing of ICD deactivation discussions, (2)
initiation of deactivation discussions, (3) advance directives, (4) barriers to discussions, and
(5) facilitators to discussions.
Conclusions:
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Despite available guidelines, conversations on device deactivation are not being undertaken
consistently. Evidence suggests lack of professional awareness of guidelines and limited
training in communication skills. To prevent distress and promote comfortable dying, there
needs to be proactive clinical and policy initiatives in the education of both professionals,
patients and relatives, about device deactivation.
Key Messages
What is already known?
● Implantable cardioverter defibrillators treat arrhythmias and prevent cardiac
arrest.
● Deactivation is needed to avoid protracted distressing death.
What are the new findings?
● Deactivation discussions are inconsistent, late or do not occur.
● Professionals are unaware of guidelines recommending early discussion.
What is the significance?
● Proactive clinical initiatives and training about device deactivation are needed.
● Research is needed on best timing for discussions.
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Introduction
Implantable cardioverter defibrillators (ICD) are used to treat life threatening cardiac arrhythmias
and prevent sudden cardiac arrest.1 The device is surgically inserted to perform four key functions:
automatic administration of defibrillation shocks to terminate ventricular fibrillation (VF) or fast
ventricular tachycardia (VT), anti-bradycardia pacing often used after a defibrillation shock as the
heart returns to normal sinus rhythm, anti-tachycardia pacing to terminate slower VT and
cardioversion of VT.2 ICD’s should be considered as a secondary prevention for patients who have
experienced one or more episodes of spontaneous, sustained VT or VF; it can also be recommended
for prophylactic primary prevention for patients who have not had prior episodes of VT or VF, but are
at high risk for arrhythmias, with the aim of improving symptoms ,quality of life and preventing
sudden death.
However, despite initial benefit, as ICD recipients age they may develop a greater risk of dying as a
result of progressive multimorbidity rather than sudden cardiac death. In these cases, defibrillation
shocks may result in the prolongation of an uncomfortable dying process, with one in three ICD
recipients experiencing multiple shocks in their last days of life which can be both painful and futile,
preventing a dignified death.3
To ensure high-quality end-of-life care, it is recommended patients should have an understanding of
the impact ICDs can have during the active process of dying and how these events could be avoided
if deactivation of the defibrillator was initiated, whilst maintaining the pacemaker function. This
should be done through open, sensitive and culturally relevant communications.2
Both the British Heart Foundation (BHF) 2013, and the European Heart Rhythm Association (EHRA)
2010, advises device deactivation discussions should be included as part of pre-implantation
informed consent, raising the issue of a future time whereby the patient’s general health may
deteriorate to such an extent that device deactivation may be appropriate.2 4 At the time of the
guideline publication, results of the EHRA survey (2010) suggested that only 4% of implant centres
were doing this.5 Indeed, current literature shows a mixed response to this proactive approach with
clinicians suggesting that raising issues related to ICD deactivation at the pre-implantation stage
might be inappropriate, since implantation of the ICD felt like a ‘second chance at life’.6 Furthermore,
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it has been reported that patients have expressed how engaging in an ICD deactivation discussion
before implantation may increase emotional distress.7
The goals of this review are: to provide an overview of the evidence on the process of initiating ICD
deactivation discussions; when they should occur; who should be involved; the use of advance
directive and barriers to these conversations. From this to provide recommendations on how to
engage in effective, patient-centred deactivation discussions.
Methods
Inherent within the aim of this systematic review is the exploration of the complexity of balancing
the duty of care to consider ICD withdrawal, when the ICD is at risk of causing harm, with the
potential distress of these conversations. As such, although systematic reviews traditionally focus on
quantitative evidence, qualitative evidence with the potential for rich explanatory data was
incorporated.
Criteria for consideration of studies for review.
Prior to searching databases an inclusion criteria was agreed by both authors; literature had to be
published in the last 10 years in the English language and refer to an adult population (over the age
of 18 years). This timeframe was chosen to reflect current practice following recommendations of
national and international guidelines.2 4 To answer the research question literature had to be on the
communication around ICD deactivation.
Identification and selection of studies.
The aim of the search was to identify and select an inclusive list of all studies that met the inclusion
criteria. MF searched the following databases from October 2019 to February 2020 with a further
search in March 2021: MEDLINE, EMBASE, CINAHL and PsycInfo.
Consensus was reached between reviewers for the specific MeSH headings and key words used for
the population: Implantable cardioverter defibrillator, ICD, automatic implantable cardioverter
defibrillator, AICD, implantable defibrillator (in relation to both patients and professionals). Search
words used for intervention: Communication, health communication, consult, inform, mention,
discuss, verbalise, talk to, vocalise, converse, address, advance care planning, advance directive, end
of life planning. Appropriate wildcards were inserted where necessary.
MF hand searched reference lists of relevant studies to identify further papers. Titles and abstracts
were inspected by MF and clearly ineligible papers or duplicates were deleted. Full copies of
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potentially eligible papers were retrieved, if full copy of the text could not be found authors were
contacted via ResearchGate.  Abstracts alone could not be used as they provided insufficient data.
Unpublished articles were included if they met the criteria for inclusion and the full text was
available. All identified full papers were independently screened by MF.
Data Extraction.
A standardised electronic checklist was agreed and created by both authors to extract data on:
general information (author and year, type of publication, country of origin, source of funding, study
characteristics, aim, study design, inclusion and exclusion criteria, recruitment procedures);
participant characteristics (participants, age, gender, ethnicity, disease characteristics); number of
participants included; and number and reason for withdrawal. Additionally, the extraction form
included three key criteria: experience of, barriers to and facilitators for ICD deactivation
communication. This was a deductive approach to answer the research question. MF extracted the
data.
Data analysis.
Critical Appraisal Skills Program (CASP) checklists (according to study type) were used by MF to
assess the quality of included papers. It was anticipated that the search strategy would produce a
diverse set of papers using different research methods.
Results
Following de-duplication, n=8063 studies were identified. During title/abstract screening and full-text
review, n=8041 studies were excluded. Primary reasons for exclusion were: unrelated to study aim,
ICD referred to ‘International Classification of Disease’, or articles could not be accessed. Ten of the
included studies were qualitative reviews,7 9-17 eight used a survey to extract data,18-25 three
retrospectively reviewed data26-28 and only one study was a randomised control trial.29
Figure 1 PRISMA flow chart showing literature selection
Five included cohort studies assessed for quality using the CASP cohort checklist scored highly. Most
of the studies were robust, and generalisable, but it was difficult to identify how studies controlled
confounding factors.23-24 26-28 15 studies were qualitative, and appraised using qualitative CASP
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checklist. These qualitative studies rarely reflected on the interactions between participants and
researcher and if all ethical considerations had been taken into account. However, for all the studies
there was a clear statement of findings.7 9-13 16-21 25 Only one randomised controlled trial was included,
and appraised using RCT CASP checklist, the study scored highly in all criteria.29 See online
supplementary material for full details of the quality assessments.
14 of the studies focused on patient experience, six on the perspectives of healthcare professionals
and two on family member experiences. There is a significant gender disparity with 93% of the
studies on patient experience having a male predominance. 12 studies were conducted in United
States of America and Canada, seven in Europe Union and three in the United Kingdom. See Table 1
for full details of included papers.












Ali-Ahmed et al 2019 United States of America Survey Healthcare professionals 124 -  - - 
Buchhalter et al 2014 United States of America Retrospective review of medical records Patients 159 79 101 (67%) 58 (33%)
Conelius et al 2013 United States of America Survey Patients 200 75 152 (76%) 48 (24%)
Fluur et al 2013 Sweden Qualitative Interviews Patients 37 64 23 (62%) 14 (38%)
Fluur et al 2014 Sweden Qualitative Interviews Family member 18 61 7 (395) 11 (61%)
Goldstein et al 2019 United States of America RCT Healthcare professionals 525 60 367 (70%) 158
(30%)
Hill et al 2018 United Kingdom Survey Healthcare professionals 262 46 199 (76%) 63(24%)
Hill et al 2019 United Kingdom Qualitative Interviews Patients 16 69 11 (70%) 5(30%)
Kramer et al 2011 United States of America Qualitative Interviews Healthcare professionals 14 - 2 (14%) 12 (86%)
Kutcher et al 2020 United States of America Qualitative Interviews Family member 5  - 0 (0%) 5(100%)
Hjelmfors et al 2014 Sweden Survey Healthcare professionals 111 51 7(6%) 104
(94%)
MacIver et al 2016 Canada Qualitative Interviews Patients 25 72 19 (76%) 6(24%)
Lee et al 2017 United States of America Qualitative Interviews Patients 6 55 3 (50%) 3(50%)
Miller et al 2019 United States of America  and
Australia
Survey Patients 240 62 175 (73%) 65 (27%)
Mooney et al 2019 Ireland Survey Patients 30 62 24(80%) 6(20%)
Mueller et al 2011 United States of America Qualitative Interviews Healthcare professionals 17 43 12 (71%) 5(29%)
Pasalic et al 2016 United States of America Retrospective review of medical records Patients 150 79 102 (68%) 48(32%)
Raphael et al 2011 United Kingdom Qualitative Interviews Patients 54 72 43 (80%) 11(20%)
Stoevelaar et al 2020 Netherlands Qualitative Interviews Patients 41 64 23 (56%) 18(44%)




Thylén et al 2014 Sweden Survey Patients 109 67 87 (80%) 22(20%)
Trussler et al 2019 Canada Retrospective review of medical records Patients 49 78 43 (88%) 6(12%)
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There was variation across the 22 included studies about when, where and who conducted ICD
deactivation discussions. In terms of timing: four studies mentioned deactivation being discussed as
part of the informed consent,7 12 16 18 seven did not specify a time,10 17 19 23 25 26 29 two during ICD
replacement,9 22 and eight as part of end-of-life care.11 13-15 21 24 27 28 One study described how these
conversations occurred across transitions including informed consent, after implantation and as part
of end-of-life care.20 The location of these discussions was not always recorded: ten were conducted
in ‘a clinical setting’,9 10 12 13 15 16 18-22 26 29 one stipulated a hospice13 and three out-patient clinics. 15 16 29
There was a lack of clarity and consensus regarding the appropriate person to initiate these
conversations. Some studies simply recorded ‘healthcare professionals’, and others clearly identified
cardiologists, heart failure nurse specialists or palliative care consultants (further details in table 2).





Where conversation happened Who conducted conversation
Ali-Ahmed et al 2019 informed consent clinical setting electrophysiologists or cardiologists
Buchhalter et al 2014 Time not specified clinical setting palliative medicine consultants
Conelius et al 2013 Time not specified   
Fluur et al 2013 ICD replacement clinical setting healthcare professionals
Fluur et al 2014 Time not specified clinical setting healthcare professionals
Goldstein et al 2019 Time not specified inpatient or outpatient setting physicians, heart failure specialist nurses
Hill et al 2018 informed consent or part of
end-of-life care
- healthcare professionals
Hill et al 2019 part of end-of-life care  healthcare professionals
Kramer et al 2011 informed consent clinical setting electrophysiologists or cardiologists
Kutcher et al 2020 part of end-of-life care hospice palliative medicine consultants
Hjelmfors et al 2014 part of end-of-life care - physicians, heart failure specialist nurses
MacIver et al 2016 informed consent - doctor
Lee et al 2017 part of end-of-life care - doctor
Miller et al 2019 ICD replacement clinical setting healthcare professionals
Mooney et al 2019 Time not specified - healthcare professionals
Mueller et al 2011 part of end-of-life care inpatient or outpatient setting doctor
Pasalic et al 2016 part of end-of-life care - physicians, heart failure specialist nurses
Raphael et al 2011 informed consent outpatients healthcare professionals
Stoevelaar et al 2020 Time not specified - doctor
Thompson et al 2019 Time not specified -  
Thylén et al 2014 part of end-of-life care - healthcare professionals
Trussler et al 2019 part of end-of-life care - healthcare professionals
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Main themes
Following data extraction on the experience, barriers and facilitators of communication five main
themes were identified: (1) timing of ICD deactivation discussions, (2) initiation of deactivation
discussions, (3) advance directives, (4) barriers to discussions, and (5) facilitators to discussions.
Timing of ICD deactivation discussions
Informed consent is the voluntary agreement given by a fully informed, competent person and is
central to both ethical and legal aspects of care. Informed consent requires effective communication
between the healthcare professional and the patient to explain the benefits, risks and alternative
treatment options.30 Therefore, prior to ICD implantation, as recommended by the BHF and EHRA,
ICD deactivation should be discussed.2 4 Raphael et al showed this recommendation is supported by
patients, who when asked in an interview when they would want to discuss ICD deactivation 52%
preferred discussion before implantation compared to just 22% who believed it should be delayed
until they were terminally ill.16
Despite this recommendation some studies report that engaging in early discussions might increase
emotional distress.7 9 11 19 A qualitative study showed that patients found talking about death too
difficult as it shifts the focus away from what they consider important which was living in the
present.9 In addition, Maclver et al reported the irony in having deactivation discussions prior to ICD
implantation: “they put in a machine that can save me … and now they are talking about turning it
off already”.7 Further literature also suggested it might be inappropriate to discuss deactivation early
since implantation felt like ‘a second chance at life’.17
One small survey recorded only 13% of patients (n=4) had spoken with their doctor or nurse,
regarding deactivation. Nevertheless, many reported they would raise the question about end-of-life
if they had multiple shocks (83%); repeated hospital admission with recurring heart problems (87%)
or towards end-of-life (97%).25
However, it is important to acknowledge that some patients never want to discuss end-of-life issues.7
17 22-24 Thompson et al found 40% of participants said they never wanted to have a conversation
concerning end-of-life care; 55% of the cohort said they would want to have their ICD battery
replaced even if they were seriously ill and suffering from a terminal disease.23 This has been
supported by Miller et al who found that patients who had already experienced a shock were more
likely to maintain defibrillation therapy “it saved my life, and I don’t want to live without it” and
would choose to avoid ICD deactivation discussions.22 One study uncovered reasons for this
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reluctance experienced by patients including that information may be confusing, the decision is best
left to the doctor and switching off may prematurely shorten life.16
Initiation of deactivation discussions
The British Heart Foundation guideline advices ICD deactivation discussions should occur, ideally
between the heart failure nurse, the patient and their chosen representative.2
However, literature suggests that many patients would prefer to leave the decision to engage in
deactivation discussions solely in the hands of clinicians.9 16 24 Fluur et al found that this was because
patients felt clinicians knew best and trusted their judgment to decide whether or not the ICD should
remain activated.9 Miller et al reported that patients trusted clinicians so much that if they did not
bring up discussion about end-of-life choices they inferred it was not important.22
In terms of which specific member of the clinical team should be involved in these discussions,
Maclver’s et al study of 17 patients reported that nine suggested a cardiologist and eight suggested
nurses.7 Similar results were supported by Hill et al with healthcare professionals recommending a
cardiologist (97%) or specialist heart failure nurse (82%).20
Despite the general consensus that specialist nurses have the necessary attributes to initiate a
discussion about deactivation, overall data shows a lack of nursing contribution to the final decision.
Kramer et al interviewed nurses who described how pre-implantation discussions were largely
physician driven. These physicians placed a strong emphasis on the benefits of the device and less
attention on future deactivation.12 The nurses in this study reported they would be better suited than
physicians to initiate end-of-life discussions, largely because they are generally more involved with
patient care and decision making after implantation. Through this greater level of interaction, the
nurses learned a great deal about their patient’s goals and preferences; these factors are important
in influencing end-of-life decisions. The current lack of nurses’ involvement was explained by one
study as a result of the structure of healthcare systems and the traditional role of physicians to
diagnose and make treatment decisions.20 Hjelmfors et al reported there may be an issue with the
lack of education and training nurses receive to have these conversations.21 The study showed that
despite most nurses thinking it appropriate for them to talk about prognosis and end-of-life decisions
with the patient, 58% were hesitant due to uncertainty of knowing how to approach the topic or
answer patient questions.21
The evidence suggests that perhaps clinicians should not be the only ones to initiate deactivation
discussions.7 11 20 21 24 Maclver et al reported that some patients would prefer that patients themselves
were the ones to start the conversation.7 They felt that if the physician initiated the discussion before
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they were ready, this could increase emotional distress. Further literature also supported this
approach stating the choice to deactivate was best left to the patient because ‘no time is really the
right time’.11
Advance Directives
To facilitate the topic of deactivation an AD, a process of formal decision making that aims to help
patients establish decisions about future care that take effect when they lose capacity, can be used.31
However, literature has shown that in the case of ICD deactivation ADs are either not being used or
their purpose is not being explained fully.9 12 14 17 19 21 23 26 27 28 In addition, Conelius et al suggested some
healthcare professionals either do not understand the ADs themselves or do not believe they are
useful.19 Buchhlater et al found  57% of participants had ADs  of these 48% were executed before
implantation.26 Worryingly, only one advance directive addressed ICD deactivation. Interestingly, this
patient executed his AD four months after implantation and died 10 years later, two days after
deactivation for end stage heart failure.
In addition to advance directives, palliative care medicine consultations (PCMC) also provide a
suitable opportunity for discussing and recording ICD deactivation wishes alongside all
life-prolonging treatments as an integral component to holistic assessment of physical, psychological,
spiritual and social care. However, reporting on a retrospective review of the medical records of 150
patients who had undergone deactivation Buchhalter et al and Pasalic et al found only two-thirds of
PCMC’s specifically addressed this aspect of care.26 27 They acknowledge this may reflect a lack of
awareness that the patient had an ICD. It is noteworthy that PCMC’s occurred significantly more
frequently in patients who requested deactivation themselves suggesting decision making capacity.
Stoevelaar et al established that not everyone was in favour of recording their preferences in a
document.17 This was due to a range of reasons including not knowing choices available or personal
preferences for end-of-life care, knowing what they wanted but worrying that their decision would
change when actually in that situation, or being doubtful that even if they expressed their choices,
they would be respected.
Barriers to discussions
Literature suggests making advance decisions about deactivation can be difficult for the patient and
their family due to lack of information or understanding. Two studies reported how family members
felt ‘left out’ from the lack of information.10 13 Fluur et al described how spouses were rarely offered
verbal or written information and had to rely on second-hand recollections following the
consultation.10 Kutcher et al reported that spouses recalled how the medical team showed great
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enthusiasm for implantation but great reluctance to consider deactivation.13 Without this support
caregivers felt lost and hopeless. In both cases caregivers were forced to turn to their own network
and educate themselves about the possibility and benefits of deactivation.
However, there is debate on whether family members should be involved in advance decision
making.9-13 17 19 20 Fluur et al revealed that spouses were often over protective which could have a
negative impact on the patient, leading to reduced social interaction and impaired communication
when it came to making advance decisions.10 One study reported nurses’ observation of family
pressure to encourage patients to keep their device, with one nurse quoting how the patient felt the
need to avoided deactivation and stay alive just for their son.12
Evidence suggests it is not family members alone who may lack an understanding on device
deactivation. Conelius et al reported patients had a lack of understanding of their medical condition
and treatment options and limited confidence in healthcare providers to decide their
treatments.19Mooney et al highlighted that patient information in respect of device management
and deactivation during serious illness or at end-of-life is limited. In their study, 17% and 20% of
patients were unable to offer an opinion when asked if they would deactivate their ICD if receiving
shocks daily, or if they had serious illness.25. Miller et al showed that understanding of the device is
crucial and that when patients had increased knowledge they were more likely to consider
deactivation. 22
Furthermore, although patients and family members may lack knowledge, clinicians can also feel
underprepared to have these conversations. Hjelmfors et al reported that more than half the nurses
surveyed hesitated when it came to initiating end-of-life discussions; in practice they lacked
confidence in answering patient questions and 91% reported a need for further training in advanced
communication skills.21
Facilitators to discussions
A key facilitator as reported by Goldstein et al is the training of physicians.29 This RCT explored the
impact of an interactive 90 minute communication skills training session on advance care planning
conversations and ICD deactivation. The single RCT involved six hospitals with heart failure programs
and an absence of protocols addressing ICD deactivation. These were randomised in a single-blinded
cluster to reduce cross contamination at the level of clinician and patient.29 The study found that
patients were more likely to have goals of care conversations, if the physicians had undertaken the
training, compared with those cared for by clinicians in the control group, (47% intervention vs. 38%
control; odds ratio: 1.53; p = 0.04).
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Shared decision making as described by Ali-Ahmed et al and Hill et al, incorporating relevant facts
about risks and benefits, facilitating accurate and timely information to inform treatment choices.18 20
In addition, Miller et al found that increasing patient knowledge decreased unnecessary procedures
including shocks in the active dying phase.22
Building supporting relationships with healthcare professionals over time allows a process rather
than one-off conversations to occur. Hjelmfors et al reported nurses were in 100% agreement on two
main facilitators for end-of-life discussions: a good relationship with the patient and repeated
opportunities.21 Moreover, Maclaver et al promoted the recognition of the palliative phase of illness,
identifying the best time to talk about deactivation being when the patient’s condition changes with
these transitions providing opportunity for conversations.7
Discussion
Alongside developments in healthcare there has been an increase in the use of ICDs to treat life
threatening cardiac arrhythmias and cardiac arrest. However, with increasing age, disease burden
and co-morbidities, these devices have the potential to cause harm with many patients experiencing
shocks as they approach death. The associated pain, distress and anxiety with possible prolongation
of the dying experience could be avoided. This review suggests that despite guidelines2 4
recommending conversations about deactivation of the defibrillator element of the device to prevent
this, these recommendations are not always translated into clinical practice. Furthermore, these
conversations are fraught with difficulties for healthcare professionals, patients and families.
To answer the research question of when, how and who should have deactivation discussions a
deductive approach was constructed which yielded both quantitative and qualitative cross-national
studies. Of the included studies there was only one randomised control trial, the rest were
observational or qualitative. Due to the diverse nature of selected articles it was not appropriate to
use traditional synthesis methods instead results were reported under pre-determined themes.
Consideration needs to be taken of the diverse healthcare systems, practices and policies when
applying the relevance of this review to practice. Overall, there is little strong evidence to support
practice when faced with the complexity of these conversations. Nevertheless, this review identifies
significant issues that deserve further discussion.
Current guidelines recommend that device deactivation discussions should be included as part of
pre-implantation informed consent.2,4 The review suggests a variety of preferences when ICD
deactivation conversations should occur and there is no overall defining answer from literature. It is
clear that as part of the informed consent process, where patients should receive a full explanation,
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of the benefits and risks of their defibrillator, ICD deactivation should be mentioned. In general,
patients concur that they want to be ‘informed’ about device deactivation prior to implantation but
lengthy discussions should be avoided until more appropriate times.
It is the role of clinicians to provide guidance and support about appropriate treatments and options
at each phase of the disease trajectory.  The review suggests there are some patients who are not
aware that deactivation is available to them. To address this, experienced, competent clinicians could
take opportunities to introduce conversations during elective ICD battery replacement, when there is
functional decline, frequent hospital admissions, on referral to palliative care and as a component of
resuscitation conversations.  Crucial to discussions is the sensitive exploration of the patient’s
readiness to talk about deactivation and tailor information and delivery to their expressed
preference.
The British Heart Foundation recommend heart failure nurse specialists, who know the patient and
have had advance communication training, should be the ones to initiate and revisit deactivation
discussions.2 These guidelines concur with general recommendations from most of the studies
reviewed. Although some studies suggest deactivation discussions are not welcomed by patients7 17
22-24 this should not deter healthcare professionals from seeking to engage in these conversations in
order to prevent distressing shocks at end-of-life. Indeed, healthcare professionals have a duty of
care to consider withdrawal of non-contributory therapies and prevent the distress caused by
resuscitation measures in those with a progressive and irreversible decline in their condition.32
Conversations should reassure the patient that device deactivation is painless, only discontinues the
shock component and does not hasten death.2
Palliative care is an approach to improve the quality of life of patients and their families facing
problems associated with life-threatening illness, offering a support system to help the patient live
as actively as possible until the end of life, and can be applicable in the early course of illness in
conjunction with other life-sustaining therapies.34 Indeed, in the UK this phased transition of
including palliative care alongside disease modifying treatments has been suggested as particularly
relevant for those with slowly progressive or fluctuating trajectories as with cardiovascular disease.8
Joint working between cardiology and palliative care could be a conduit for advance care planning
conversations including deactivation. However, this contrasts with US models which are defined by a
sharper transition to palliative care accompanied by a cessation of curative care and is illustrated by
the 63 patients who received late referrals to palliative care, who all had a poor or terminal
prognosis, and for whom median survival after deactivation was just 2 days.27
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The main issue, that many studies in the review support, is deactivation discussions are being left
until the impending death of the patient. A study by Kim et al suggests one possible reason is that
ICD is primarily considered a life-saving therapy, for many patients and healthcare professionals’
deactivation is considered a controversial issue leading to a delay in discussion.35
The inclusion of cross-national literature means the review is subjected to impact of variations in
healthcare systems around the world. The American College of Cardiology/American Heart
Association and Heart Rhythm Society advises patients with an ICD to make a device specific advance
directive when nearing end-of-life.36 This approach appears to differ from that in Europe as illustrated
by a 6-country, cluster-randomised European advance care planning study where only 10% of
patients who received the intervention had an advance directive in their hospital files. Although not
specifically related to ICD deactivation, this illustrates the differences in cross-national approaches to
advance directives.37
Reported barriers suggested from this literature review and supported by other studies38 include:
lack of professional teaching and a knowledge deficit of patients regarding deactivation. To improve
professional training a quality improvement project by Javid et al found targeted teaching, compared
to posters or emails, had the biggest improvement in the occurrence of deactivation discussions.39
Goldstein et al randomised control trial found the intervention group that received communication
training were more likely to discuss goals of care than the control.29 This suggests education and
targeted workshops can help increase professional’s awareness and confidence. To support patient
and relative knowledge verbal information should be supplemented by written education materials.
Establishing early conversations and having a process of continued dialogue with experienced health
care professionals can help with the processing of information resulting in appropriate timing of
deactivation. This in turn may help decrease unnecessary harm and distress and promote
comfortable dying.
The review highlights that despite guidelines,2 4 which provide advice on how and who should be
having device deactivation discussions, the opportunity for these conversations are not offered or
undertaken on a consistent basis. Reasons could include a lack of professional awareness of
guidelines or that current teaching practice commonly includes the reasons for implanting life
sustaining devices, but fails to acknowledge deactivation. Literature suggests without education and
training in communication skills to explain these complex issues with clarity, and where possible,
encourage advance care planning discussions, these conversations remain limited. One option could
be to include ICD deactivation education alongside teaching on do-not-attempt-resuscitation.
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A strength of this review is that only one author was involved in selecting, extracting and evaluating
the available evidence, providing internal consistency. However, this increases the risk of bias by
having only one reviewer. In hindsight if MF had conducted a pilot search this would have illustrated
the issue of the abbreviation ICD also referring to International Classification of Disease and would
have better limited the number of studies to be filtered. Furthermore, the lack of response from
authors to requests full text articles meant that potential studies were excluded.
In summary, this review shows that there needs to be a proactive clinical and policy initiative in the
education of both professionals, and patients and relatives about device deactivation. Moreover,
healthcare professionals should be taught how to communicate these complex issues in a clear and
compassionate manner to ensure timely deactivation of the shock element of the ICD to facilitate a
comfortable, natural death.  Further research could be conducted on the most effective way for this
to be implemented.
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